A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis
A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis
A study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active Rheumatoid Arthritis (RA) who have completed 12 weeks of study treatment in Study GA29350. Eligible participants from Study GA29350 who elect to participate will receive treatment with GDC-0853 twice daily (BID) in an open-label fashion for 52 weeks, followed by a safety follow-up period of 8 weeks.
Inclusion Criteria:
Exclusion Criteria:
Ciudad Autonoma Buenos Aires, C1055AAF, Argentina
Ciudad Autonoma Buenos Aires, C1128AAE, Argentina
Ciudad Autonoma Buenos Aires, C1430CKE, Argentina
Curtiba, Paraná 80030-110, Brazil
Rio de Janeiro, Rio de Janeiro 21941-913, Brazil
Moscow, Moscow Oblast 115522, Russia
Moscow, Moscow Oblast 119049, Russia
Yekaterinburg, Sankt-Peterburg 620043, Russia
Yaroslavl, Volgograd Oblast 150051, Russia
Yaroslavl, Yaroslavl Oblast 150062, Russia
Kharkiv, Kharkiv Governorate 61176, Ukraine
Ivano-Frankivsk, KIEV Governorate 76008, Ukraine
Kyiv, KIEV Governorate 1023, Ukraine
Kyiv, KIEV Governorate 2091, Ukraine
Lviv, KIEV Governorate 79010, Ukraine
Lviv, KIEV Governorate 79014, Ukraine
Dnipro, Tavria Okruha 49008, Ukraine
Zaporizhzhya, Tavria Okruha 69065, Ukraine
Lutsk, Volhynian Governorate 43024, Ukraine